Tag: Nancie Archin

The latent HIV reservoir is a major barrier to HIV cure. Despite advancements in keeping viral loads below detectable limits, HIV-1 still exists within a latent reservoir in vivo and viral replication returns when anti-retroviral therapy (ART) is interrupted. Nancie M. Archin, PhD, and Edward P. Browne, PhD, sought to...

HIV cure strategies that aim to induce viral reactivation for immune clearance leverage latency reversal agents to modulate host pathways, which directly or indirectly facilitate viral reactivation. Inhibition of BET (bromo and extra-terminal domain) family member BRD4 reverses HIV latency, but enthusiasm for the use of BET inhibitors in HIV...

Human Immunodeficiency virus (HIV) infection is regulated by various host cell factors that combine to influence viral transcription and latency. To understand the complex relationship between the host cell and HIV-1 latency, Edward Browne, PhD, Nancie M. Archin, PhD, and David Margolis, MD, performed a lentiviral CRISPR screen that targeted a...

Investigators with the Institute for Global Health and Infectious Diseases (IGHID) participated in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. Following are some highlights.   In a CROI preview, Joe Eron, MD, was interviewed for the “Going Anti-Viral” IAS-USA podcast, discussing the...

Nancie M. Archin, PhD, researcher with the Institute for Global Health and Infectious Diseases, and assistant professor of medicine in the division of infectious diseases, received the “Diversity in Science and Excellence” award from the International Society for Antiviral Research. The $5,000 award goes towards a scientist of any group...

HIV/AIDS has been around for approximately 40 years, but many researchers say the end is in sight. The question is, will it be in our lifetime or just around the corner? This is a spotlight on the HIV CURE Center, comprising approximately 55 researchers and students, featuring David Margolis, MD, the...

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

Angela Wahl, PhD, a member of the Institute for Global Health & Infectious Diseases (IGHID), the International Center for the Advancement for Translational Science, and assistant professor in the division of infectious diseases has received a $3.2 million R01 award to study the role of microglia in HIV latency and...

Global health research is a collaborative process, and each researcher at the Institute for Global Health & Infectious Diseases contributes a piece to solving the puzzle of disease and morbidity. With a new academic year underway, read what some of our investigators are working on to improve the health of global populations....